| Code | CSB-RA006163MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to BAT-4706, targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T cell activation by competing with CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, effectively dampening immune responses. This inhibitory mechanism plays a vital role in maintaining immune homeostasis and preventing autoimmunity. Dysregulation of CTLA4 signaling is implicated in various conditions, including autoimmune diseases, transplant rejection, and cancer, where tumors exploit this pathway to evade immune surveillance.
BAT-4706 represents an important reference antibody for investigating CTLA4 biology and immune checkpoint modulation. This biosimilar provides researchers with a reliable tool for studying T cell regulation, immune tolerance mechanisms, and checkpoint inhibitor pathways. It supports investigations into immunotherapy strategies, autoimmune disease mechanisms, and the development of novel therapeutic approaches targeting immune modulation. The antibody is valuable for exploring CTLA4's role in both physiological immune regulation and pathological conditions.
There are currently no reviews for this product.